ClinicaliQ Trial Snapshot
- Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 — Recruiting • Phase III • NCT07486934.
- A drug called zeleciment basivarsen was tested to see if it safely and effectively treats myotonic dystrophy type 1.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1). Conditions: Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert Interventions: zeleciment basivarsen (DYNE-101), Placebo Lead Sponsor: Dyne Therapeutics Planned Enrollment: 150 participants